A total of 32 companies entered the public market this past week, with the week’s 7 IPOs joined by one direct listing and 24 SPACs. In the largest US IPO of the year to date, Coupang (CPNG) upsized and priced above the upwardly...read more
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised $190 million by offering 10 million shares at $19, the high end of the upwardly revised range of $18 to $19. The company offered 1 million more...read more
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $167 million by offering 9...read more
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.4 million shares at a price...read more
US IPO Weekly Recap: Coupang completes year's largest IPO and Roblox direct-lists in a 7 IPO week
A total of 32 companies entered the public market this past week, with the week’s 7 IPOs joined by one direct listing and 24 SPACs. In the largest US IPO of the year to date, Coupang (CPNG) upsized and priced above the upwardly...read more
IBD biotech Prometheus Biosciences prices further upsized IPO at $19, the high end of the upwardly revised range
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised $190 million by offering 10 million shares at $19, the high end of the upwardly revised range of $18 to $19. The company offered 1 million more...read more
Prometheus Biosciences raises deal size by 33% ahead of $167 million IPO
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $167 million by offering 9...read more
Phase 1 biotech Prometheus Biosciences sets terms for $125 million IPO
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.4 million shares at a price...read more